NEFL and secondary progressive multiple sclerosis: Intrathecal administration of rituximab in SPMS patients was tried in the past with unsatisfactory results, demonstrating inadequate depletion of B cells in the CNS and persistence of the axonal damage marker, the neurofilament light chain [102].